Tectonic Therapeutics TECX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $71.32M+12.3% | $63.49M+12.8% | $56.3M+4.9% | $53.69M+23.2% | $43.58M+5.4% | ||
| $21.72M+5.7% | $20.55M+1.7% | $20.21M-1.7% | $20.56M+4.0% | $19.76M+18.7% | ||
| $93.04M+10.7% | $84.04M+9.8% | $76.51M+3.0% | $74.26M+17.2% | $63.35M+9.2% | ||
| $93.04M+10.7% | $84.04M+9.8% | $76.51M+3.0% | $74.26M+17.2% | $63.35M+9.2% | ||
| -$93.04M-10.7% | -$84.04M-9.8% | -$76.51M-3.0% | -$74.26M-17.2% | -$63.35M-9.2% | ||
| $51K-19.0% | $63K-13.7% | $73K-13.1% | $84K-11.6% | $95K-10.4% | ||
| $11.03M-2.3% | $11.3M+7.9% | $10.47M+10.0% | $9.52M+47.6% | $6.45M+51.3% | ||
| $10.78M-3.0% | $11.12M+9.1% | $10.19M+10.1% | $9.25M+97.7% | $4.68M+13,271% | ||
| —— | -$72.92M-9.9% | -$66.32M-2.0% | -$65M-10.8% | -$58.67M-1.2% | ||
| $26.43M+54.2% | $17.14M+1.5% | $16.89M0.0% | $16.89M+6.1% | $15.91M+4.2% | ||
| -$83.49M-12.6% | -$74.15M-10.2% | -$67.3M-2.0% | -$65.98M-12.5% | -$58.67M-1.2% | ||
| -$4.46-10.1% | -$4.05— | —— | —— | —— | ||
| -$4.46-10.1% | -$4.05— | —— | —— | —— | ||
| 74.5M+2.2% | 72.9M+15.6% | 63M+6.7% | 59.1M+36.4% | 43.3M+57.3% | ||
| 74.5M+2.2% | 72.9M+15.6% | 63M+6.7% | 59.1M+36.4% | 43.3M+57.3% | ||
| -$61K+41.9% | -$105K-1,067% | -$9K-1,000% | $1K-97.7% | $44K+4,300% | ||
| $83.55M+12.5% | $74.26M+10.3% | $67.31M+2.0% | $65.98M+12.5% | $58.62M+1.1% | ||
| -$200K-68.1% | -$119K+42.2% | -$206K-13.2% | -$182K-30.9% | -$139K+72.7% | ||
| -$93.04M-10.7% | -$84.04M-9.8% | -$76.51M-3.0% | -$74.26M-17.2% | -$63.35M-9.2% | ||
| -$91.72M-11.0% | -$82.66M-10.3% | -$74.96M-3.2% | -$72.63M-17.7% | -$61.72M-9.5% | ||
| -$91.72M-11.0% | -$82.66M-10.3% | -$74.96M-3.2% | -$72.63M-17.7% | -$61.72M-9.5% | ||
| -$93.04M-10.7% | -$84.04M-9.8% | -$76.51M-3.0% | -$74.26M-17.2% | -$63.35M-9.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Tectonic Therapeutics profitable?
- Tectonic Therapeutics is not currently profitable: it reported a net loss of $83.5M over the trailing twelve months.
- What is Tectonic Therapeutics's earnings per share?
- Tectonic Therapeutics's diluted EPS over the trailing twelve months is $-4.46.
- Where does Tectonic Therapeutics's income statement data come from?
- Every line is extracted from Tectonic Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.